June 16, 2026
5 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Dual-target CAR T-cell therapy exhibits ‘profound’ remission in systemic sclerosis
A dual-target CD19/BCMA chimeric antigen receptor T-cell therapy yielded “profound, sustained” remission in 11 patients with refractory systemic sclerosis, according to data presented at the EULAR 2026 Congress.“As we all know, despite advances in immunosuppressive, biologic and antifibrotic therapies, a subset of patients with refractory, progressive systemic sclerosis
1,357 words~6 min read
